Market Cap
$462.3B
ABBV
AbbVie Inc.
$262.82 ▲ +1.11%
Prev close $259.93Market cap$462.3B
ConsensusStrong Buy
12-mo target$278.86 (+6.1%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10)37 New Institutional Positions13 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on ABBV right now — valuation, ownership and activity at a glance.
Cap Size
Mega Cap
Analyst Consensus
Strong Buy (82%)
Inst. Holders
50 funds
Inst. Value
$244.1B
Inst. Activity
37 buys / 13 sells
Insider Activity
$0.00 buy / $18.9M sell
Insider Net $
-$18.9M
Social Sentiment
71° Bullish
SEC Reports
14
Congressional
2 trades
Price chart 30d +1.0%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Insider
RAPP EDWARD J was granted 129 shares
Director @ $261.59 ($33.7K)
Sep 30, 2026 Insider
Quaggin Susan E was granted 59 shares
Director @ $261.59 ($15.4K)
Sep 28, 2026 Event
Arcturus Therapeutics, Inc. v. AbbVie Inc. et al
Court ruling (casd) — Docket: 3:25-cv-02494
Sep 25, 2026 Event
JUVMO
Original Approval — Type 1 - New Molecular Entity — TABLET
Sep 21, 2026 clinical_trial_readout
Sep 16, 2026 SEC Results Pending: Eluxadoline (Phase 2) — Completed 35d ago
Trial: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome W
New Mexico federal court denied AbbVie's motion for a preliminary injunction against H.B. 78, a state law restricting ma
COURT-RULING — Impact 5/10
Sep 14, 2026 Congress
Sep 3, 2026 SEC Pete Sessions sell
$15,001 - $50,000 — House
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology assets zumilokibart
8-K — Impact 4/10
Analyst ratings buy % +17.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
82% rate it Buy or better · 39 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | MAINTAIN | Buy | 55% |
| Aug 20, 2026 | Piper Sandler | MAINTAIN | Overweight | 54% |
| Aug 17, 2026 | Wells Fargo | MAINTAIN | Overweight | 54% |
| Aug 13, 2026 | Wolfe Research | UPGRADE | Outperform | 52% |
| Aug 11, 2026 | BNP Paribas | MAINTAIN | Neutral | — |
| Aug 10, 2026 | Evercore ISI Group | MAINTAIN | Outperform | 59% |
| Aug 6, 2026 | Berenberg | MAINTAIN | Buy | 31% |
| Aug 5, 2026 | Erste Group | UPGRADE | Buy | 55% |
| Aug 4, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Aug 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 10 | 22 | 7 | 0 | 0 | 82% | |
| Aug 1, 2026 | 9 | 22 | 7 | 0 | 0 | 82% | |
| Jul 1, 2026 | 9 | 22 | 8 | 0 | 0 | 79% | |
| Jun 1, 2026 | 9 | 22 | 9 | 0 | 0 | 78% | |
| May 1, 2026 | 8 | 22 | 10 | 0 | 0 | 75% | |
| Apr 1, 2026 | 7 | 21 | 11 | 0 | 0 | 72% | |
| Mar 1, 2026 | 7 | 20 | 12 | 0 | 0 | 69% | |
| Feb 1, 2026 | 7 | 18 | 12 | 0 | 0 | 68% |
Price targets
Where 28 covering analysts think ABBV trades over the next 12 months.
$278.86 +6.1% upside Buy
Current$262.82 Low$200.00 Median$285.00 High$328.00 28 analysts
$200.00$328.00
Analyst rating Buy· 1.7/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
71°
Bullish
BearishNeutralBullish
Recent posts
$SRPT WMS Event next week. New CEO Severino that was at $ABBV...
▲ 1 · 💬 0· ⚡ 0.5
The market thinks Revolution Medicines(RVMD)is a biotech. I think it’s becoming big pharma
▲ 1 · 💬 0· ⚡ 0.5
$ABBV $225 June 5 .15 cents
▲ 1 · 💬 0· ⚡ 0.5
What are your top bets for the next 5 years. Here's mine base on trends/fundamentals.
▲ 1 · 💬 0· ⚡ 0.5
A mechanical PMCC workflow I tested on ABBV + TSM (faster LEAP cost reduction than theta-only
▲ 1 · 💬 1· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
14 SEC filing reports analyzed · 5 bullish, 1 bearish, 1 mixed, 7 neutral · avg impact 4.5/10.
BULLISHANALYST-UPGRADE1/10
Canaccord Genuity initiates ABBV at Buy with $262 PT — +28.6% upside
Apr 21, 2026
NEUTRALCOURT-RULING5/10
New Mexico federal court denied AbbVie's motion for a preliminary injunction against H.B. 78, a stat
Sep 16, 2026
NEUTRAL8-K4/10
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics, adding late-stage immunology
Sep 3, 2026
NEUTRAL8-K4/10
AbbVie entered into an underwriting agreement to issue and sell $10.0 billion aggregate principal am
Aug 6, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 28, 2026
Enforcement
Arcturus Therapeutics, Inc. v. AbbVie Inc. et al
Court ruling (casd) — Docket: 3:25-cv-02494
Sep 25, 2026
Clinical Trial
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Phase Phase 3 — COMPLETED
Sep 25, 2026
FDA
JUVMO
Original Approval — Type 1 - New Molecular Entity — TABLET
Sep 21, 2026
Clinical Trial
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
Phase Phase 2 — COMPLETED
Sep 21, 2026
clinical_trial_readout
Results Pending: Eluxadoline (Phase 2) — Completed 35d ago
Trial: Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children Sponsor: AbbVie Phase: Ph
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $3.84 | $3.77–$3.87 | 106.7% | -0.0% | 6↑ 7↓ | $17.3B | 19 |
| Next Q | $3.86 | $3.77–$3.98 | 42.5% | -0.1% | 1↑ 13↓ | $18.3B | 18 |
| Current FY | $14.01 | $13.90–$14.12 | 40.1% | -0.0% | 1↑ 20↓ | $67.6B | 26 |
| Next FY | $16.26 | $15.13–$17.59 | 16.1% | -0.1% | 10↑ 9↓ | $73.5B | 25 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $3.844 | — |
| 7d ago | $3.844 | -0.001 |
| 30d ago | $3.844 | -0.001 |
| 60d ago | $3.835 | +0.009 |
| 90d ago | $3.849 | -0.005 |
Institutional ownership
Which big funds own ABBV (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $244.1B total value (969,469,898 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 37 institutions added/increased vs 13 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 149,488,412 | $37.6B | 15.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 115,396,098 | $29.0B | 11.9% | — |
| STATE STREET CORP | 82,596,748 | $20.8B | 8.5% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 48,477,996 | $12.2B | 5.0% | — |
| JPMORGAN CHASE & CO | 47,862,796 | $12.2B | 5.0% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 46,998,433 | $11.8B | 4.8% | — |
| MORGAN STANLEY | 38,901,001 | $9.8B | 4.0% | — |
| Capital Research Global Investors | 30,101,551 | $7.6B | 3.1% | — |
| NORGES BANK | 25,554,538 | $6.4B | 2.6% | NEW |
| BANK OF AMERICA CORP /DE/ | 21,237,764 | $5.3B | 2.2% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 25,554,538 | — | $6.4B |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 6,897,816 | 5,055,589 | -26.7% | $1.3B |
| Boston Partners | ADD | 3,434,210 | 4,784,316 | +39.3% | $1.2B |
| CITADEL ADVISORS LLC | DOUBLED | 490,285 | 3,169,783 | +546.5% | $797.6M |
| MARSHALL WACE, LLP | DOUBLED | 1,061 | 2,990,512 | +281757.9% | $752.5M |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | DOUBLED | 1,091,285 | 2,885,557 | +164.4% | $726.1M |
| TD ASSET MANAGEMENT INC | TRIM | 3,920,076 | 2,578,333 | -34.2% | $648.8M |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | 1,780,456 | 2,374,888 | +33.4% | $597.6M |
| Corient Private Wealth LP | DOUBLED | 2,203,650 | 19,562,230 | +787.7% | $557.3M |
| D. E. Shaw & Co., Inc. | DOUBLED | 672,990 | 2,102,316 | +212.4% | $529.0M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
21 insiders, 50 transactions. Net -$18.9M — $0.00 bought, $18.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | RAPP EDWARD J | Director | AWARD | 129 | $261.59 | $33.7K |
| Sep 30, 2026 | Quaggin Susan E | Director | AWARD | 59 | $261.59 | $15.4K |
| Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | EXERCISE | 32,710 | $79.02 | $2.6M |
| Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | SELL | 32,710 | $250.00 | $8.2M |
| Jun 30, 2026 | Quaggin Susan E | Director | AWARD | 62 | $251.64 | $15.6K |
| Jun 30, 2026 | RAPP EDWARD J | Director | AWARD | 134 | $251.64 | $33.7K |
| May 8, 2026 | BURNSIDE WILLIAM H.L. | Director | AWARD | 1,118 | — | — |
| May 8, 2026 | Davis Jennifer L. | Director | AWARD | 1,118 | — | — |
| May 8, 2026 | Quaggin Susan E | Director | AWARD | 1,118 | — | — |
| May 8, 2026 | AUSTIN ROXANNE S | Director | AWARD | 1,118 | — | — |
Congressional trades
ABBV trades disclosed by members of Congress, with disclosure delay.
2 members · 0 buys / 2 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Pete Sessions | R | HOUSE | SELL | $15,001 - $50,000 | AbbVie Inc | Sep 21, 2026(8d) |
| May 5, 2026 | Josh Gottheimer | D | HOUSE | SELL | $1,001 - $15,000 | AbbVie Inc | Jun 4, 2026(31d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for ABBV.
Shares short
19,494,556
Settlement Sep 15, 2026
Change vs prior
-0.1%
Semi-monthly cycle
Days to cover
4.5
At avg daily volume
Of shares outstanding
≈1.1%
Estimate — not % of float
All ABBV filing & press-release reports (14)
- Canaccord Genuity initiates ABBV at Buy with $262 PT — +28.6% upsideApr 21, 2026
- COURT-RULING reportSep 16, 2026
- 8-K reportSep 3, 2026
- 8-K reportAug 6, 2026
- COURT-RULING reportAug 5, 2026
- INST-CLUSTER reportAug 3, 2026
- 8-K reportJul 31, 2026
- COURT-RULING reportJul 29, 2026
- 8-K reportJul 3, 2026
- COURT-RULING reportMay 18, 2026
- 8-K reportApr 29, 2026
- 8-K reportApr 21, 2026
- DEFA14A reportMar 23, 2026
- CLUSTER reportMar 6, 2026